Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 7/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2506398 | 1.00 | BACE1 (0.42) | BACE1HTR2CHTR2AHTR2BMC4R | |
| SCHEMBL2506405 | 1.00 | BACE1 (0.42) | BACE1HTR2CHTR2AHTR2BMC4R | |
| SCHEMBL2878234 | 0.86 | HTR2C (0.49) | HTR2CKDM1AMAPTPKM | |
| SCHEMBL2883975 | 0.86 | HTR2C (0.49) | HTR2CKDM1AMAPTPKM | |
| SCHEMBL2878236 | 0.86 | HTR2C (0.49) | HTR2CKDM1AMAPTPKM | |
| SCHEMBL3436383 | 0.83 | TSHR (0.40) | HTR2CHTR2AHTR2BKDM1AMAPT | |
| SCHEMBL15998586 | 0.83 | TSHR (0.40) | HTR2CHTR2AHTR2BKDM1AMAPT | |
| SCHEMBL1818075 | 0.82 | MEN1 (0.44) | BACE1HTR2CHTR2AHTR2BMC4R | |
| SCHEMBL1818076 | 0.82 | MEN1 (0.44) | BACE1HTR2CHTR2AHTR2BMC4R | |
| SCHEMBL1818079 | 0.82 | MEN1 (0.44) | BACE1HTR2CHTR2AHTR2BMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2025-04-03 | — | — | US | disclosed |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES, LLC | 2024-12-05 | — | — | US | disclosed |
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-08-06 | — | — | US | disclosed |
| CN-113967258-B | FAP-activated therapeutic agents and related uses | 塔夫茨大学信托人 | 2024-07-02 | — | — | CN | disclosed |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | BACH BIOSCIENCES, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| EP-4299134-A2 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | Bach Biosciences, LLC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-3154594-B1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | BACH BIOSCIENCES LLC (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20220296621-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | BACH BIOSCIENCES, LLC | 2022-09-22 | — | — | US | disclosed |
| WO-2008119005-A1 | 3,4-DEHYDRO-PROLINE-CONTAINING INHIBITORS OF DIPEPTIDYLPEPTIDASE IV | TRUSTEES OF TUFTS COLLEGE (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116053-A2 | FAP-ACTIVATED CHEMOTHERAPEUTIC COMPOUNDS, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008116054-A1 | INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1948243-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | Aeris Therapeutics, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080057491-A1 | Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-03-06 | — | — | US | disclosed |
| WO-2008022015-A2 | RETRO-INVERSO INCRETIN ANALOGUES, AND METHODS OF USE THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007146104-A2 | SUBSTRATES AND INHIBITORS OF ANTIPLASMIN CLEAVING ENZYME AND METHODS OF USE | MCKEE PATRICK A (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | GEORGETOWN UNIVERSITY | 2007-11-15 | — | — | US | disclosed |
| WO-2007055950-A2 | POLYCATION-POLYANION COMPLEXES, COMPOSITIONS AND METHODS OF USE THEREOF | AERIS THERAPEUTICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070110813-A1 | Polycation-polyanion complexes, compositions and methods of use thereof | AERIS THERAPEUTICS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12121505-B2 | Fap-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | BACE1 1070/4885HTR2C 4760/4885HTR2A 4466/4885 |
| US-20250108031-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | BACE1 1070/4885HTR2C 4760/4885HTR2A 4466/4885 |
| US-12023316-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | BACE1 1070/4885HTR2C 4760/4885HTR2A 4466/4885 |
| US-20070265255-A1 | SYNTHESIS, STRUCTURE AND USE OF BISOXAZOLIDINES FOR ASYMMETRIC CATALYSIS AND SYNTHESIS | ADH5, ADH1C, ADH1A | BACE1 3471/4885HTR2C 821/4885HTR2A 1611/4885 |
| US-20220296621-A1 | FAP-Activated Therapeutic Agents, and Uses Related Thereto | FAP, FIBP, GOT1 | BACE1 921/4885HTR2C 4630/4885HTR2A 4376/4885 |
| US-12053450-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | BACE1 1070/4885HTR2C 4760/4885HTR2A 4466/4885 |
| US-11925655-B2 | FAP-activated therapeutic agents, and uses related thereto | FAP, FIBP, GOT1 | BACE1 921/4885HTR2C 4630/4885HTR2A 4376/4885 |
| US-20240398842-A1 | FAP-ACTIVATED THERAPEUTIC AGENTS, AND USES RELATED THERETO | FAP, FIBP, GOT1 | BACE1 853/4885HTR2C 4614/4885HTR2A 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.